BioSpace News Archive

Business

Mednow Provides Revenue Guidance on Fiscal Q3 2022, a Projected Record C$5 - C$5.5 Million in Quarterly Revenue, Q/Q Growth of Approx. 175%

Mednow Inc. is pleased to provide a corporate update on its upcoming fiscal Q3 2022 quarterly earnings, which will be released in June 2022.

April 26, 2022
·
11 min read
Business

NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center’s Herbert Irving Comprehensive Cancer Center

NexImmune, Inc. today announced a preclinical research collaboration with Columbia University Irving Medical Center’s (CUIMC) Herbert Irving Comprehensive Cancer Center (HICCC).

April 26, 2022
·
4 min read
Business

Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 5, 2022

Iovance Biotherapeutics, Inc. will report its first quarter financial results on Thursday, May 5, 2022.

April 26, 2022
·
5 min read
Pharm Country

Holmusk Announces Publication of Seminal Paper on Real-World Evidence (RWE) Platform NeuroBlu

Holmusk is pleased to share with the scientific community in-depth details about its platform via the publication of a paper in BMJ Open.

April 26, 2022
·
4 min read
Drug Development

BioEclipse Therapeutics™ Awarded Almost $8 Million Grant by California Institute for Regenerative Medicine (CIRM) to Fund Ongoing Phase 1 CRX100 Cancer Immunotherapy Clinical Trial

BioEclipse Therapeutics announced today it has been awarded a $7,999,689.00 grant by the California Institute for Regenerative Medicine (CIRM) to support its ongoing clinical study: A Phase 1, open-label, dose-escalation study of CRX100 in patients with advanced solid tumors.

April 26, 2022
·
3 min read
Biotech Bay

89bio to Host Key Opinion Leader Webinar on Severe Hypertriglyceridemia (SHTG)

89bio, Inc. announced that it will host a key opinion leader webinar on severe hypertriglyceridemia on Wednesday, May 4, 2022 at 11:00 a.m. PT/ 2:00 p.m. ET.

April 26, 2022
·
5 min read
Pharm Country

VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer

VBL Therapeutics (Nasdaq: VBLT), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ofra-vec (ofranergene obadenovec or VB-111) in combination with paclitaxel for the treatment of platinum-resistant ovarian cancer.

April 26, 2022
·
6 min read
Business

Compass Therapeutics Announces Appointment of Two New Directors to its Board

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today is pleased to announce the appointment of two new directors to its board.

April 26, 2022
·
5 min read
Business

Talis Biomedical to Announce First Quarter 2022 Financial Results on May 10, 2022

Talis Biomedical Corporation announced that it will report first quarter financial results on Tuesday, May 10, 2022, after market close.

April 26, 2022
·
1 min read
Business

Rhythm Pharmaceuticals to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022

Rhythm Pharmaceuticals, Inc. today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, May 3, 2022 to report its first quarter 2022 financial results and provide a corporate update.

April 26, 2022
·
7 min read